Flerie
NET ASSET VALUE – 30 April 2025
MARKN.
On the 30 April 2025 Flerie AB's Net Asset Value (NAV) was SEK 3,965 million and NAV per share was SEK 50.79.
Allocation of NAV | Share of portfolio company | Fair value (MSEK) | Part of NAV per share (SEK) | Share of NAV |
Product Development | ||||
Prokarium | 42% | 452 | 5.80 | 11.4% |
Xspray Pharma | 18% | 231 | 2.96 | 5.8% |
Empros Pharma | 79% | 204 | 2.62 | 5.2% |
KAHR Medical | 31% | 182 | 2.33 | 4.6% |
Lipum | 57% | 182 | 2.33 | 4.6% |
Atrogi | 37% | 176 | 2.25 | 4.4% |
Xintela | 61% | 165 | 2.11 | 4.1% |
Microbiotica | 10% | 129 | 1.65 | 3.2% |
Geneos Therapeutics | 12% | 93 | 1.19 | 2.3% |
AnaCardio | 14% | 69 | 0.89 | 1.7% |
Mendus | 24% | 60 | 0.77 | 1.5% |
Toleranzia | 53% | 60 | 0.77 | 1.5% |
EpiEndo Pharmaceuticals | 9% | 54 | 0.70 | 1.4% |
Synerkine Pharma | 43% | 54 | 0.70 | 1.4% |
Vitara Biomedical | 11% | 48 | 0.62 | 1.2% |
Buzzard Pharmaceuticals | 14% | 32 | 0.40 | 0.8% |
Sixera Pharma | 24% | 27 | 0.35 | 0.7% |
Egetis Therapeutics | 2% | 22 | 0.28 | 0.6% |
Alder Therapeutics | 21% | 17 | 0.22 | 0.4% |
Amarna Therapeutics | 58% | 11 | 0.14 | 0.3% |
Strike Pharma | 16% | 9 | 0.11 | 0.2% |
Total | 2,277 | 29.17 | 57.4% | |
Commercial Growth | ||||
Symcel | 30% | 192 | 2.46 | 4.8% |
NorthX Biologics | 92% | 189 | 2.42 | 4.8% |
Chromafora | 30% | 73 | 0.93 | 1.8% |
Nanologica | 43% | 47 | 0.61 | 1.2% |
Frontier Biosolutions | 2% | 18 | 0.23 | 0.5% |
Bohus Biotech | 45% | 17 | 0.21 | 0.4% |
Total | 536 | 6.87 | 13.5% | |
Limited Partnerships, total | 90 | 1.15 | 2.3% | |
Assets related to Portfolio companies | 266 | 3.41 | 6.7% | |
Other assets and liabilities | 795 | 10.18 | 20.0% | |
Net asset value | 3,965 | 50.79 | 100.0% | |
Datum | 2025-05-07, kl 08:00 |
Källa | MFN |

Cashback är begränsad till högst $100. Värdet på dina investeringar kan gå upp eller ner. Du riskerar ditt kapital.